{
    "organizations": [],
    "uuid": "2ad55df95fcbe610e99ad193d401dec774ed4e1e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vifor-pharma-vfmcrp-and-cara-thera/brief-vifor-pharma-vfmcrp-and-cara-therapeutics-to-develop-and-commercialise-cr845-injection-for-chronic-kidney-disease-associated-pruritus-idUSFWN1SU08J",
    "ord_in_thread": 0,
    "title": "BRIEF-Vifor Pharma: VFMCRP And Cara Therapeutics To Develop And Commercialise CR845 Injection For Chronic Kidney Disease-Associated Pruritus",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 23 (Reuters) - VIFOR PHARMA AG:\n* VFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-05-23T13:06:00.000+03:00",
    "crawled": "2018-05-24T20:16:59.029+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "vifor",
        "pharma",
        "ag",
        "vfmcrp",
        "cara",
        "therapeutic",
        "develop",
        "commercialise",
        "cr845",
        "injection",
        "chronic",
        "kidney",
        "pruritus",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}